Major reconstructions at Takeda
LMI TV went to see Takeda’s manufacturing site in Asker, Norway, to get a grip of the investments and reconstruction necessary to comply with the Falsified Medicines Directive.
To avoid falsified medicines to reach European patients, the EU commission released their Falsified Medicines Directive. The directive introduces two features on prescription drugs. All packs should have a seal that is impossible to break unless you open the pack, also called a tamper evidence. If the seal is broken, it shows that the pack has been tampered with. The second is a 2-dimensional code containing information such as a unique identifier of the pack. The manufacturer will upload the unique identifier to a database, and when pharmacies scan the code, an automated look-up in the system is generated to check whether the pack is genuine.
The 2-dimensional code may look small and insignificant to the consumer; however, it is a very big undertaking for the pharmaceutical industry to introduce these features. Takeda shows us why.
This video is currently in Norwegian only.